“…8 Nanomaterials like inorganic nanoparticles, liposomes, dendrimers, and polymers have gained extensive attention in the field of drug and gene delivery, due to their incomparable advantages, such as higher drug loading capacity, lower dose and administration frequency, good biocompatibility (less side effects), high stability, enhanced bioavailability and biodegradability, targeted applications with less invasive theranostic techniques, decreased acquired drug resistance, negligible toxicity and immunogenicity, reduced off-target toxicity, feasibility for various routes of administration (intranasal, oral, and intravenous, and intramuscular injection), sustained and controlled drug release, unique properties (physical, electronic, chemical, and optical), and effective tracing of drug delivery. 3,9 These nanomaterials are being designed and developed as safe, effective, feasible, and practical tools for diagnosing and treating diseases of the CNS. 10 The current interest in functionalized NPs crossing the BBB is reflected in the number of publications per year, which showed a relatively stable growth trend between 1995 and 2023 in general (Figure 1A).…”